BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

NEWS: BDSI Completes Acquisition of ELYXYB Learn More >

Building a Clinical Knowledge Base

BDSI supports research to help advance the understanding of treatment options for serious and debilitating chronic conditions.

Investigator-Sponsored Research Program

BDSI makes support available for clinical studies developed and sponsored by independent investigators, as long as the studies demonstrate clear scientific merit and involve treatments for serious and debilitating chronic conditions. Support may include funding, product, or both.

Areas of interest currently being explored include:
  • The clinical impact of buprenorphine’s mechanism of action, efficacy, and safety
  • The process and clinical impact of transitioning chronic-pain patients to alternative therapy options
  • Buprenorphine patient outcomes and their impact on healthcare
  • Patient outcomes and the value peripherally-acting mu-opioid receptor antagonists (PAMORAs) provide in healthcare
  • Clinical impact of the PAMORAs on special patient populations in treating OIC

Sponsor-investigators are encouraged to submit study proposals for consideration. Please download the form and email it upon completion to

Download application form

Support for research proposals is awarded based on:

Scientific merit icon Scientific merit
Patient safety icon Patient safety
Unmet medical need icon Unmet medical need
Availability of funds icon Availability of funds
Feasibility of the proposal icon Feasibility of the proposal
Alignment with BDSI's areas of interest icon Alignment with BDSI's areas of interest

Medical Education Grants

BDSI is committed to supporting independent, high-quality educational programs for healthcare professionals that contribute to the improvement of patient care in therapeutic areas where the business has research and clinical interests.

BDSI provides financial assistance to support accredited or unaccredited independent education programming, including educational symposia, seminars, and/or sessions directed by certified healthcare professionals, where the grant recipient is solely responsible for developing the content and managing the educational program.

For more information, please download our PDF on independent medical education grants. Download now

Medical Resources for Healthcare Professionals

This is an online medical resource for scientific and clinical information on BioDelivery Sciences products and is intended for healthcare providers practicing in the United States. If you have questions about investigator-sponsored research, please contact your Medical Science Liaison or complete the form below and hit Submit.

Research Information Request

Asterisks denote required fields

Recent BDSI News

November 3, 2021

Total Net Revenue of $41.1 Million , an Increase of 4% versus Prior Year Strong profitability with GAAP EPS of $0.07 , EBITDA Margin of 27% and $7.0 million Operating Cash Flow Closed acquisition of ELYXYB, the first FDA-approved, ready-to-use oral solution for acute migraine with potential

Read more
October 21, 2021

RALEIGH, N.C. , Oct. 21, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced the appointment of John Golubieski as Chief Financial

Read more
October 20, 2021

RALEIGH, N.C. , Oct. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced today that it will report its third quarter 2021 financial results before the open of

Read more
More news

Upcoming Events

There are no events to display

Stay Connected

Stay up to date on the latest news

Get started now
November 29, 2021BDSI $2.82/ - -3.09%
Data provided by Nasdaq. Minimum 15 minutes delayed.